|Clinical and Regulatory|
|Event Type:||Phase 1/2 Results|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|Disease and Treatment|
|Indication:||Duchenne muscular dystrophy associated cardiomyopathy|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|Co. Name:||Capricor Therapeutics|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
Detailed Event Description from Company Announcement
With heart disease being one of the primary drivers of death and disability in older DMD patients, each step we take toward better managing DMD is an important one. We look forward to sharing additional milestones from the HOPE-Duchenne trial in the coming months, including its top-line results, which are expected in the first quarter of 2017.